Antibodies to IL-6 and use thereof
View Patent ↗The present invention is directed to antibodies and fragments thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V H , V L and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6. These antibodies may bind at least one of soluble IL-6, cell surface expressed IL-6, IL-6/IL-6R and/or prevent the association of IL-6 and IL-6R, the association of IL-6/IL-6R and gp130 and or the formation of IL-6/IL-6R/gp130 multimers and thereby inhibit a biological effect associated with any of the foregoing.
1. An anti-human IL-6 antibody or antibody fragment comprising a variable light chain comprising the CDR 1 sequence of SEQ ID NO: 4, the CDR 2 sequence of SEQ ID NO: 5, and the CDR 3 sequence of SEQ ID NO: 6, and a variable heavy chain comprising the CDR 1 sequence of SEQ ID NO: 7, the CDR 2 sequence of SEQ ID NO: 8 or SEQ ID NO:120, and the CDR 3 sequence of SEQ ID NO: 9.
2. An anti-human IL-6 antibody or antibody fragment comprising the variable heavy chain in SEQ ID NO:2, 18 or 19 and the variable light chain contained in SEQ ID NO:3 or 20.
3. An anti-human IL-6 antibody or antibody fragment which comprises the variable heavy chain in SEQ ID NO: 19 and the variable light chain contained in SEQ ID NO:20.
4. An anti-human IL-6 antibody or antibody fragment that comprises the CDRs in an anti-human IL-6 antibody according to claim 1 or 2 wherein the variable heavy and light chains are each at least 90% identical to the variable heavy and light chains in SEQ ID NO:19 and 20 respectively.
5. An anti-human IL-6 antibody or antibody fragment according to claim 1 that is selected from the group consisting of chimeric, humanized, and human antibodies or antibody fragments.
6. An anti-human IL-6 antibody or antibody fragment according to claim 1 that is selected from the group consisting of scFvs, camelbodies, nanobodies, IgNAR (single-chain antibodies derived from sharks) and F ab , F ab′ or F (ab′)2 fragments.
7. An anti-human IL-6 antibody or antibody fragment according to claim 1 , 2 or 3 that is non-glycosylated.
8. An anti-human IL-6 antibody or antibody fragment according to claim 1 , 2 or 3 that comprises a human constant domain.
9. An anti-human IL-6 antibody or antibody fragment according to claim 8 that is an IgG1, IgG2, IgG3or IgG4antibody.
10. An anti-human IL-6 antibody or antibody fragment according to claim 1 , 2 or 3 which contains an Fc region that has been modified to alter at least one of effector function, half-life, proteolysis, or glycosylation.
11. The anti-human IL-6 antibody or antibody fragment of claim 10 wherein the Fc region contains a mutation that alters or eliminates glycosylation.
12. An anti-human IL-6 antibody or antibody fragment according to claim 1 , 2 or 3 which is a humanized antibody or antibody fragment.
13. An anti-human IL-6 antibody or antibody fragment according to claim 1 , 2 or 3 which is directly or indirectly attached to a detectable label or therapeutic agent.
14. An anti-human IL-6 antibody or antibody fragment according to claim 1 , wherein said antibody binds to IL-6 with a dissociation constant (K D ) of less than or equal to 5×10 −10 .
15. An anti-human IL-6 antibody or antibody fragment according to claim 1 , 2 or 3 which further comprises an effector moiety.
16. The anti-human IL-6 antibody or antibody fragment of claim 15 , wherein the effector moiety is a detectable moiety or a functional moiety.
17. The antibody or antibody fragment of claim 16 wherein said detectable moiety is a fluorescent dye, an enzyme, a substrate, a bioluminescent material, a radioactive material, or a chemiluminescent material.
18. The antibody or antibody fragment of claim 16 , wherein said functional moiety is streptavidin, avidin, biotin, a cytotoxin, a cytotoxic agent, or a radioactive material.
19. An anti-IL-6 antibody or antibody fragment according to claim 4 , wherein said antibody comprises a variable light or heavy chain which respectively are at least 95% identical to the variable light or variable heavy chain polypeptides contained in SEQ ID NOs: 20 and 19.
20. A anti-IL-6 antibody or antibody fragment according to claim 4 wherein said antibody or antibody fragment comprises a variable light or heavy chain which is at least 98% identical to the variable light or variable heavy chain polypeptides respectively contained in SEQ ID NOs: 20 and 19.
21. An isolated anti-IL-6 antibody or antibody fragment according to claim 4 , wherein said antibody or antibody fragment comprises a variable light or heavy chain which is at least 99% identical to the variable light or variable heavy chain polypeptides respectively contained in SEQ ID NOs: 20 and 19.
22. A composition containing an anti-human IL-6 antibody or antibody fragment according to claim 1 , 2 or 3 and a carrier or excipient.
23. The composition of claim 22 that is suitable for therapeutic or diagnostic use.
24. The composition of claim 23 which further comprises at least one stabilizer.
25. An anti-human IL-6 antibody or antibody fragment which comprises the variable heavy chain in SEQ ID NO: 18 and the variable light chain contained in SEQ ID NO:20.
26. The anti-IL-6 antibody or antibody fragment of claims 1 which comprises human IgG1constant domains.
27. The anti-IL-6 antibody or antibody fragment of claims 3 which comprises human IgG1 constant domains.
28. The anti-IL-6 antibody or antibody fragment of claims 25 which comprises human IgG1constant domains.